Gökten Dilara Bulut, Mercan Rıdvan
Department of Rheumatology, Tekirdag Namik Kemal University, Turkey.
Mediterr J Rheumatol. 2025 Jan 21;36(1):122-127. doi: 10.31138/mjr.130424.amo. eCollection 2025 Mar.
Calciphylaxis, which literally means 'protection through calcification', is a fatal disease characterised by ischemic necrosis of cutaneous tissue resulting from vascular intimal fibroplasia, thrombi, and calcifications in the arterioles. The pathophysiology involves the accumulation of calcium in the skin, vascular space, and adipose tissue due to abnormal serum levels of calcium, phosphorus, and parathyroid hormone (PTH), particularly in patients with end-stage renal disease (ESRD). The clinical presentation typically involves severe ischemic and neuropathic pain, which may occur independently of skin lesions. There are no specific diagnostic criteria or laboratory tests; the disease is primarily recognised based on clinical findings. There is no definitive information on treatment due to the incomplete understanding of its mechanism; therefore, the prevention of calciphylaxis is of paramount importance. Upon examination of cases in the literature, a mortality rate of 34% is observed despite appropriate treatment and care. Given its rarity, calciphylaxis is prone to being overlooked. Through this review presenting two cases seen in our rheumatology clinic, our aim is to raise awareness about calciphylaxis which can mimic vasculitis, and promote early diagnosis.
钙过敏,字面意思是“通过钙化实现保护”,是一种致命疾病,其特征是由于血管内膜纤维增生、血栓形成以及小动脉钙化导致皮肤组织缺血性坏死。病理生理学涉及由于血清钙、磷和甲状旁腺激素(PTH)水平异常,尤其是终末期肾病(ESRD)患者,导致钙在皮肤、血管腔隙和脂肪组织中蓄积。临床表现通常包括严重的缺血性和神经性疼痛,其可能独立于皮肤病变而出现。目前尚无特定的诊断标准或实验室检查;该疾病主要基于临床发现来识别。由于对其机制的理解不完整,目前尚无关于治疗的确切信息;因此,预防钙过敏至关重要。在查阅文献中的病例时,尽管进行了适当的治疗和护理,仍观察到死亡率为34%。鉴于其罕见性,钙过敏容易被忽视。通过本次对我们风湿科门诊所见的两例病例的综述,我们的目的是提高对可模仿血管炎的钙过敏的认识,并促进早期诊断。